Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,361 | -5,026 | -42,194 | -19,337 | -14,235 |
| Depreciation Amortization | 2,871 | 1,901 | 3,745 | 2,801 | 1,815 |
| Accounts receivable | N/A | -193 | 5,557 | 5,557 | 5,195 |
| Accounts payable and accrued liabilities | 198 | 243 | -2,702 | -2,596 | -2,275 |
| Other Working Capital | -2,511 | -2,774 | 2,326 | 2,754 | 4,248 |
| Other Operating Activity | -6,665 | -4,901 | 8,148 | -851 | -1,253 |
| Operating Cash Flow | $-18,468 | $-10,750 | $-25,119 | $-11,673 | $-6,505 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -182 | -129 | -153 | -85 | -44 |
| Purchase Of Investment | -31,335 | -31,230 | N/A | N/A | N/A |
| Sale Of Investment | 11,376 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-20,140 | $-31,359 | $-153 | $-85 | $-44 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 765 | N/A | N/A |
| Debt Repayment | -65 | -32 | -127 | -96 | -65 |
| Common Stock Issued | 20 | 20 | 67,164 | 4 | 2 |
| Other Financing Activity | -671 | -383 | -1,029 | -773 | -661 |
| Financing Cash Flow | $-716 | $-394 | $66,773 | $-864 | $-724 |
| Exchange Rate Effect | 0 | -28 | 18 | N/A | N/A |
| Beginning Cash Position | 56,566 | 56,566 | 15,047 | 15,047 | 15,047 |
| End Cash Position | 17,242 | 14,034 | 56,566 | 2,426 | 7,775 |
| Net Cash Flow | $-39,324 | $-42,532 | $41,519 | $-12,621 | $-7,272 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,468 | -10,750 | -25,119 | -11,673 | -6,505 |
| Capital Expenditure | -182 | -129 | -197 | -129 | -44 |
| Free Cash Flow | -18,649 | -10,879 | -25,317 | -11,802 | -6,549 |